A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (NCT05552976)

🧪 Interventions in This Study

• Mezigdomide (DRUG)
• Carfilzomib (DRUG)
• Dexamethasone (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (207 Sites)

Showing the first 25 of 207 sites.

• Local Institution - 0046 — Mobile, Alabama
• Local Institution - 0005 — Cerritos, California
• Local Institution - 0190 — Irvine, California
• Local Institution - 0187 — Los Angeles, California
• Local Institution - 0344 — Santa Rosa, California
• Local Institution - 0339 — Stockton, California
• Local Institution - 0279 — Newark, Delaware
• Local Institution - 0341 — Fort Myers, Florida
• Local Institution - 0342 — St. Petersburg, Florida
• Local Institution - 0340 — West Palm Beach, Florida
• Local Institution - 0348 — Atlanta, Georgia
• Local Institution - 0291 — Atlanta, Georgia
• Saint Alphonsus Regional Medical Center — Boise, Idaho
• Local Institution - 0289 — Annapolis, Maryland
• Local Institution - 0204 — Boston, Massachusetts
• Local Institution - 0346 — Minneapolis, Minnesota
• Local Institution - 0222 — Little Silver, New Jersey
• Local Institution - 0199 — The Bronx, New York
• Local Institution - 0322 — Cleveland, Ohio
• Local Institution - 0172 — Columbus, Ohio
• Local Institution - 0321 — Providence, Rhode Island
• Local Institution - 0338 — Greer, South Carolina
• Local Institution - 0349 — Chattanooga, Tennessee
• Local Institution - 0323 — Nashville, Tennessee
• Local Institution - 0337 — Fort Worth, Texas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Relapsed or Refractory Multiple Myeloma

• A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma — Anchorage, Alaska
• A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma — Toronto, Ontario
• A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma — Tucson, Arizona
• A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma — Duarte, California
• A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama

Explore by condition: All Relapsed or Refractory Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.